Methylphenidate Patent Expiration
Methylphenidate is Used for treating Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients. It was first introduced by Noven Pharmaceuticals Inc
Methylphenidate Patents
Given below is the list of patents protecting Methylphenidate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Cotempla Xr-odt | US11166947 | Effective dosing of a child for the treatment of ADHD with methylphenidate | Jan 25, 2038 | Neos Theraps Inc |
| Cotempla Xr-odt | US9072680 | Compositions comprising methylphenidate complexed with ion-exchange resin particles | Jun 28, 2032 | Neos Theraps Inc |
| Cotempla Xr-odt | US9089496 | Compositions comprising methylphenidate complexed with ion-exchange resin particles | Jun 28, 2032 | Neos Theraps Inc |
| Cotempla Xr-odt | US8840924 | Compositions and methods of making rapidly dissolving ionically masked formulations |
Jun 05, 2026
(Expired) | Neos Theraps Inc |
| Daytrana | US8632802 | Device for transdermal administration of drugs including acrylic polymers |
Oct 07, 2025
(Expired) | Noven Pharms Inc |
| Daytrana | US9034370 | Device for transdermal administration of drugs including acrylic polymers |
Oct 07, 2025
(Expired) | Noven Pharms Inc |
| Daytrana | US9668981 | Device for transdermal administration of drugs including acrylic based polymers |
Oct 07, 2025
(Expired) | Noven Pharms Inc |
| Daytrana | US6210705 | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
Sep 30, 2018
(Expired) | Noven Pharms Inc |
| Daytrana | US6348211 | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
Sep 30, 2018
(Expired) | Noven Pharms Inc |
| Daytrana | US5958446 | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
Dec 12, 2012
(Expired) | Noven Pharms Inc |
Methylphenidate's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Methylphenidate:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
